The first pharmacological approach tested in patients with acute leukemias was the anti-sense oligonucleotide Oblimersen sodium (Genasense), which targets the first six codons (the initiation codon region) of BCL2 mRNA. The gene discussed is BCL2; the disease is acute leukemia.